Prescient Therapeutics (ASX: PTX)
Live Investor Briefing
Register for an Upcoming Webcast
Please join Prescient Therapeutics CEO Steven Yatomi-Clarke for a special live investor briefing.
Event Details:
Date: Registr for an Upcoming Webcast
In the session, Steven will discuss:
- The company’s promising pipeline of cancer treatments with two targeted therapies, cell therapy enhancements and CAR-T
- Its work in the most exciting area of cancer research “next gen” CAR-T and its OmniCAR platform
- A strong balance sheet with $20m in the bank following oversubscribed Share Purchase Plan and Placement
This is a live and interactive session, you simply need an internet connection to participate. Don’t miss out, spots are limited – This is a FREE event.
Book Your Spot
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets have been engaged to help manage our investor communications.
What is a 708 investor?FEATURE SPEAKER
Steven Yatomi-Clarke
CEO and Managing Director
Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.